Skip to content

effect of lavender in Alzheimer's disease patients

Metabolomic investigation of blood and urine of Alzheimer's disease patients treated with lavender in combination with donepezil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200720048149N1
Enrollment
60
Registered
2022-06-25
Start date
2016-09-22
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease. Alzheimer's disease

Interventions

Intervention 1: Intervention group: Patients with confirmed Alzheimer's disease were randomly selected and receive 3 capsules containing lavender extract daily. Extraction is prepared by hydro-alcoho

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: Alzheimer's patients in stage 1 and 2, whose diagnosis of Alzheimer's disease is based on ICD10 / DSM-IV criteria. These criteria include: 1- Multiple cognitive deficits that include memory impairment and at least one of the signs of aphasia, apraxia, agnosia and executive dysfunction, 2- Existence of cognitive deficits severe enough to cause occupational and social dysfunction and show Provides a reduction in the previous performance level.

Exclusion criteria

Exclusion criteria: End-stage patients of Alzheimer's disease According to ICD10 / DSM-IV criteria, patient with a cognitive impairment is excluded from the study if dementia is not diagnosed in the delirium period. Patients with cognitive deficits are due to other central nervous system diseases such as Parkinson's, or systemic diseases such as hypothyroidism and substance abuse.

Design outcomes

Primary

MeasureTime frame
Mini–Mental State Examination (MMSE) score. Timepoint: At the beginning of the study and after one month of intervention. Method of measurement: Mini–Mental State Examination.;Alteration of blood metabolites. Timepoint: Before the intervention and one month after the intervention. Method of measurement: Nuclear magnetic resonance (NMR) device.;Altered urinary metabolites. Timepoint: Before the intervention and one month after the intervention. Method of measurement: Nuclear magnetic resonance (NMR)device.

Secondary

MeasureTime frame
Awareness of time. Timepoint: Before the intervention and one month after the intervention. Method of measurement: With MMSE test score.;Awareness of location. Timepoint: Before the intervention and after a month. Method of measurement: With MMSE test score.;Memory. Timepoint: Before the intervention and after a month. Method of measurement: With MMSE test score.;Attention and calculation. Timepoint: Before the intervention and after a month. Method of measurement: With MMSE test score.

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthakimeh zali

Shahid Beheshti University of Medical Sciences

hakimehzali@gmail.com+98 21 2243 9848

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026